Patent classifications
C07K7/04
IMMUNOTHERAPY FOR ANGIOGENIC DISEASE
The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Immunotherapy for angiogenic disease
The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Immunotherapy for angiogenic disease
The present invention provides a pharmaceutical composition containing a cancer antigen peptide for treatment and prevention of angiogenic diseases.
Peptide combinations for use in the diagnosis of schizophrenia
Provided is a composition including a combination of at least one short peptide and at least one peptide dimer, in defined ratio, to which autoantibodies found in elevated levels in schizophrenic patients bind.
Peptide combinations for use in the diagnosis of schizophrenia
Provided is a composition including a combination of at least one short peptide and at least one peptide dimer, in defined ratio, to which autoantibodies found in elevated levels in schizophrenic patients bind.
SYNTHETIC PEPTIDE, RELATIVE ARTIFICIAL ANTIGEN, RELATIVE ANTI-EHD2 ANTIBODY AND PREPARATION METHOD THEREOF AND USE THEREOF
The present application provides a synthetic peptide with an amino acid sequence SEQ ID NO: 1 plus a cysteine at its N-terminal, an artificial antigen, an antibody specific to a human EHD2, a method for preparing an antibody specific to the human EHD2 protein and adopted to an immunohistochemical method for EHD2 detection as well as cancer diagnosing and prognosing.
SYNTHETIC PEPTIDE, RELATIVE ARTIFICIAL ANTIGEN, RELATIVE ANTI-EHD2 ANTIBODY AND PREPARATION METHOD THEREOF AND USE THEREOF
The present application provides a synthetic peptide with an amino acid sequence SEQ ID NO: 1 plus a cysteine at its N-terminal, an artificial antigen, an antibody specific to a human EHD2, a method for preparing an antibody specific to the human EHD2 protein and adopted to an immunohistochemical method for EHD2 detection as well as cancer diagnosing and prognosing.
TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME
Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.
TRANSFECTION COMPLEXES AND METHODS OF USING THE SAME
Disclosed herein are transfection complexes comprising at least one cell surface ligand; at least one helper lipid component; and a transfection enhancer. Also disclosed are pharmaceutical compositions comprising the disclosed transfection complexes, and a pharmaceutically acceptable carrier. Further, disclosed are methods of transfecting a cell, the method comprising the steps of: obtaining a transfection complex as disclosed; and contacting a cell with the transfection complex.
Synthetic peptide, relative artificial antigen, relative anti-EHD2 antibody and preparation method thereof and use thereof
The present application provides a synthetic peptide with an amino acid sequence SEQ ID NO: 1 plus a cysteine at its N-terminal, an artificial antigen, an antibody specific to a human EHD2, a method for preparing an antibody specific to the human EHD2 protein and adopted to an immunohistochemical method for EHD2 detection as well as cancer diagnosing and prognosing.